Community based outpatient treatment of multidrug-resistant tuberculosis

Dheda, K.
April 2003
Thorax;Apr2003, Vol. 58 Issue 4, p347
Academic Journal
Discusses the abstract of the article 'Community-based thearpy for multidrug-resistant tuberculosis,' by C. Mitnick and colleagues, which appeared in a 2003 issue of the 'New England Journal of Medicine.' Assessment of treatment feasibility; Predictors of poor outcome in patients receiving community-based outpatient treatment.


Related Articles

  • Drug resistant TB is spreading worldwide. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);11/06/99, Vol. 319 Issue 7219, p1220 

    Provides information on the 1999 report by the Harvard Medical School and financier George Soro's Open Society Institute regarding a multidrug resistant tuberculosis. Comments from Paul Farmer, author of the report; Countries with high rates of drug resistant tuberculosis; Other findings of the...

  • Treatment for tuberculosis and standard of care.  // WHO Drug Information;2001, Vol. 15 Issue 2, p61 

    Reports on the treatment and standard of care for tuberculosis. Definition of multidrug-resistant tuberculosis; Difficulty of treating multidrug-resistant tuberculosis; Debate about whether to consider multidrug-resistant tuberculosis treatable or untreatable.

  • Preventing multidrug-resistant tuberculosis. Bloch, Alan B.; Simone, Patricia M. // JAMA: Journal of the American Medical Association;2/14/96, Vol. 275 Issue 6, p487 

    Editorial. Suggests the knowledge, treatment and prevention of multidrug-resistant tuberculosis (MDR TB) in the United States. Evidence of improvements in control aspects from statistical information from the Centers for Disease Control and Prevention; The use of molecular techniques and their...

  • Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four? Grard, Soazic; Catho, Gaud; Valour, Florent; Bouaziz, Anissa; Perpoint, Thomas; Braun, Evelyne; Biron, François; Miailhes, Patrick; Ferry, Tristan; Chidiac, Christian; Souquet, Pierre-Jean; Couraud, Sébastien; Lina, Gérard; Goutelle, Sylvain; Veziris, Nicolas; Dumitrescu, Oana; Ader, Florence // Open Forum Infectious Diseases;Fall2015, Vol. 2 Issue 4, p1 

    Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side...

  • Clinical Outcomes of Estonian Patients with Primary Multidrug-Resistant versus... Lockman, Shahin; Kruuner, Annika; Binkin, Nancy J.; Levina, Klaudia; Yong Chang Wang; Hoffner, Sven E.; Tappero, Jordan W. // Clinical Infectious Diseases;2/1/2001, Vol. 32 Issue 3, p373 

    Compares the clinical outcomes among patients with primary multidrug-resistant (MDR) tuberculosis and patients with pansusceptible tuberculosis. Volume of literature on the clinical outcomes of patients with MDR tuberculosis; Success of treatment for MDR tuberculosis patients; Deaths associated...

  • The Treatment of Multidrug-Resistant Tuberculosis in Turkey. Tahaoğlu, Kemal; Törün, Tülay; Sevim, Tülin; Ataç, Güliz; Kir, Altan; Karasulu, Levent; Özmen, İpek; Kapaklı, Nilüfer // New England Journal of Medicine;7/19/2001, Vol. 345 Issue 3, p170 

    Background: We evaluated the results of treatment in 158 consecutive patients with multidrug-resistant tuberculosis who were treated at our center in Istanbul, Turkey. Methods: A total of 21 female patients and 137 male patients (age range, 15 to 68 years) received treatment for...

  • Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Sotgiu, Giovanni; Lange, Christoph; Richardson, Morgan D'Arcy; Matteelli, Alberto; Centis, Rosella; Eker, Barbara; Guenther, Gunar; Spanevello, Antonio; Migliori, Giovanni Battista // Journal of Antimicrobial Chemotherapy (JAC);Oct2009, Vol. 64 Issue 4, p879 

    A letter to the editor is presented in response to the study "Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis," by W. J. Koh et al, published in the "Journal of Antimicrobial Chemotherapy."

  • Fears over incurable TB deepen after re-testing.  // CME: Continuing Medical Education;Jun2012, Vol. 30 Issue 6, p219 

    The article reports that the re-test conducted by the National Tuberculosis Institute in Bangalore confirm that the strains of tuberculosis (TB) in India resist all first- and second-line drugs.

  • THE PROBLEM OF MULTIDRUG RESISTANT TUBERCULOSIS. Mitrea, Mirela; Bîrluţiu, Victoria; DEAC, M. // Acta Medica Transilvanica;sep2011, Vol. 16 Issue 3, p332 

    After the 1940s it was believed that tuberculosis (TB) will be eradicated. Nowdays there is a recrudescence of the disease since the '80s, recorded difficulties associated with resistance to therapy, the emergence of multidrug-resistant tuberculosis (MDR TB) and since 2006 the extensive...


Read the Article


Sign out of this library

Other Topics